Genomic Approaches to Common Chronic Disease - Ancillary to ARIC
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Genomic Approaches to Common Chronic Disease|
- Cardiovascular disease and its risk factors [ Time Frame: One year ]
- Additional common chronic disease risk factors [ Time Frame: One year ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||July 1985|
The Atherosclerosis Risk in Communities Study (ARIC), sponsored by the National Heart, Lung and Blood Institute (NHLBI), is a prospective epidemiologic study conducted in four U.S. communities. ARIC is designed to investigate the etiology and natural history of atherosclerosis, the etiology of clinical atherosclerotic diseases, and variation in cardiovascular risk factors, medical care and disease by race, gender, location, and date.
ARIC includes two parts: the Cohort Component and the Community Surveillance Component. The Cohort Component began in 1987, and each ARIC field center randomly selected and recruited a cohort sample of approximately 4,000 individuals aged 45-64 from a defined population in their community. A total of 15,792 participants received an extensive examination, including medical, social, and demographic data. These participants were reexamined every three years with the first screen (baseline) occurring in 1987-89, the second in 1990-92, the third in 1993-95, and the fourth and last exam was in 1996-98. Follow-up occurs yearly by telephone to maintain contact with participants and to assess health status of the cohort.
In the Community Surveillance Component, currently ongoing, these four communities are investigated to determine the community-wide occurrence of hospitalized myocardial infarction and coronary heart disease deaths in men and women aged 35-84 years. Hospitalized stroke is investigated in cohort participants only. The study conducts community surveillance of inpatient heart failure (ages 55 years and older) and cohort surveillance outpatient heart failure events beginning in 2005.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00808353
|Principal Investigator:||Eric Boerwinkle, PhD||Univeristy of Texas Houston Health Science Center School of Public Health|